Navigation Links
Acute Coronary Syndrome (ACS) Drug Market

NEW YORK, July 5, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Acute Coronary Syndrome (ACS) Drug Market .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market.

Our report gives you revenue forecasts to 2021 for treating acute coronary syndrome (ACS). You will find market predictions at total world, submarket, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our study covers ACS treatments, including those for unstable angina (UA) and acute myocardial infarction (AMI). You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents and their subgroups to 2021. 

You will see how drugs like Plavix, Effient/Efient, ReoPro, Integrilin, Aspirin Cardio, Lovenox, Angiomax/Angiox, Arixtra and Metalyse/TNKase will perform to 2021. Our report provides many revenue forecasts and discussions, giving answers you need. 

In particular, we discuss the R&D pipeline. There are opportunities for original and generic drugs for treating acute coronary syndrome from 2011 onwards. 

We help you to assess the ACS treatment industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see what the future holds. 

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We include 78 tables and charts and a research interview (shown in the accompanying lists).

Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

• You will receive hard data for the acute coronary syndrome treatments industry and market - especially our revenue forecasts to 2021

• You will discover revenue predictions to 2021 for the overall ACS market and its components, seeing where the highest revenue growth will occur

• You will see the revenue prospects to 2021 for 12 leading drugs, with discussions of market potential and competition

• You will find ACS revenue predictions to 2021 for leading national markets (US, Japan, UK, Germany, France, Spain, Italy, China and India)

• You will learn how the ACS treatment industry will change from 2011 to 2021

• You will review the technologies in development, assessing potential among the R&D product candidates for ACS

• You will investigate competition and opportunities influencing the industry and market from 2011 onwards

• You will see what will stimulate and restrain the industry and market from 2011

• You will investigate commercial requirements - with therapeutic needs and sales opportunities discussed

• You will analyse opportunities and challenges for established companies and those seeking to enter the ACS market

• You will view opinions from our survey.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for cardiovascular drugs. 

Order our report now to gain industry and market information you need 

Our report can benefit everybody interested in the industry and market for treating acute coronary syndrome. We give predictions and answers you need. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Acute Coronary Syndrome (ACS) Treatment Market Review

1.2 Aims, Scope and Format of the Report

1.2.1 Scope of the Report

1.2.2 Chapter Outlines

1.3 Research and Analysis Methods

2. Cardiovascular Diseases (CVD): Overview

2.1 Financial and Social Costs 

2.2 Coronary Artery Disease (CAD)

2.3 Acute Coronary Syndrome (ACS)

2.3.1 Unstable Angina (UA)

2.3.2 Acute Myocardial Infarction (AMI) NSTEMI/Non-Q-wave Myocardial Infarction STEMI/Q-wave Myocardial Infarction

2.4 Most ACS Patients are UA/NSTEMI

2.5 Risk Factors

3. Treatment of Acute Coronary Syndrome

3.1 Therapeutic Categories for ACS

3.2 Antiplatelet Drugs/Platelet Aggregation Inhibitors

3.2.1 ADP Receptor Antagonists/Thienopyridines

3.2.2 Glycoprotein Inhibitors

3.2.3 COX Inhibitors and Aspirin

3.3 Anticoagulants

3.3.1 Heparins

3.3.2 Vitamin K Antagonists and Warfarin

3.4 Fibrinolytics

3.4.1 Streptokinase and Urokinase

3.4.2 Tissue Plasminogen Activators (tPA)

3.4.3 Other Fibrinolytic Agents

3.5 Anti-Ischaemic Drugs

3.5.1 Nitrates

3.5.2 Beta-Blockers

3.6 Antihypertensives

3.7 Lipid-Lowering Treatments

4. ACS Treatment Market, 2010-2021

4.1 Scope and Limitations

4.2 The World ACS Treatment Market in 2010

4.3 The Platelet Aggregation Inhibitors Drug Class Dominates the World ACS Treatment Market

4.4 Plavix: The Leading ACS Drug in 2010

4.5 The Five Leading Drugs Accounted for over 70% of the World ACS Treatment Market in 2010

4.6 The World ACS Treatment Market, 2011-2021

4.6.1 Changing Market Shares of the Leading Therapeutic Classes

5. Platelet Aggregation Inhibitors Market, 2010-2021

5.1 Platelet Aggregation Inhibitors Market, 2010

5.2 Platelet Aggregation Inhibitors Market, 2011-2021

5.3 ADP Receptor Antagonists

5.3.1 Plavix (Clopidogrel): Maintaining its Market Leading Position Generic Competition Due to Strike in the USACS Market Branded Competition: Marketed and in the Pipeline Sales Forecast for Plavix in ACS, 2011-2021

5.3.2 Effient/Efient (Prasugrel), Daiichi Sankyo Company/Eli Lilly Effient or Plavix? Sales Forecast for Effient, 2011-2021

5.4 Glycoprotein IIb/IIIa Inhibitor

5.4.1 ReoPro (Abciximab), Eli Lilly/Centocor Ortho Biotech Strong Competition from Integrilin Market Presence of ReoPro Biosimilar Sales Forecast for ReoPro, 2011-2021

5.4.2 Integrilin (Eptifibatide), Merck/GlaxoSmithKline (GSK) Broader Indications Offering Advantage? Sales Forecast for Integrilin, 2011-2021

5.5 COX Inhibitors

5.5.1 Aspirin Cardio, Bayer HealthCare Pharma Aspirin Cardio Sales, 2010 Aspirin Cardio Sales Forecast, 2011-2021 OTC Treatment for the Prevention of Cardiovascular Disease?

5.6 The Future of Platelet Aggregation Inhibitors

6. Anticoagulant Treatment Market, 2010-2021

6.1 Anticoagulant Treatment Market, 2010

6.2 Anticoagulants Treatment Market, 2011-2021

6.3 Injectable Anticoagulants

6.3.1 Lovenox/Clexane (Enoxaparin), Sanofi-Aventis Lovenox is Approved for Multiple Indications: About 10% of its 2010 Sales Were from its Use in ACS Competition for Lovenox Sales Forecast for Lovenox, 2011-2021

6.3.2 Angiomax/Angiox (Bivalirudin), The Medicines Company Strong Sales Performance in EU, 2010 Sales Forecast for Angiomax, 2011-2021

6.3.3 Arixtra (Fondaparinux), GSK Arixtra Sales for Use in ACS Patients, 2010 Generic Competition for Arixtra Sales Forecast for Arixtra, 2011-2021

6.4 Oral Anticoagulants

6.4.1 Coumadin (Warfarin), Bristol-Myers Squibb Competition from Generics and Pipeline Drugs Sales Forecast for Coumadin, 2011-2021

6.5 The Future of the Anticoagulants Market

7. Fibrinolytics Market, 2010-2021

7.1 Fibrinolytics Market, 2010

7.2 Fibrinolytics Market, 2011-2021

7.3 Second-Generation Drug Metalyse/TNKase: Leading the Category

7.3.1 Mode of Administration May Give Metalyse the Edge

7.3.2 ASSENT Clinical Studies: A Mixed Message

7.3.3 Sales Forecast for Metalyse/TNKase, 2011-2021

7.4 Activase/Actilyse

7.4.1 Sales Forecast for Activase/Actilyse, 2011-2021

8. Leading National Markets for ACS Drugs, 2010-2021

8.1 Leading National Markets in 2010

8.2 Leading National Markets: Sales Forecasts, 2011-2021

8.3 The US ACS Treatment Market, 2011-2021

8.4 Japanese ACS Treatment Market, 2011-2021

8.5 Leading ACS Treatment Markets in Europe, 2011-2021

8.6 Chinese ACS Treatment Market, 2011-2021

8.7 Indian ACS Treatment Market, 2011-2021

9. The ACS Drugs R&D Pipeline

9.1 Pipeline Products in the ACS Treatment Industry

9.2 The Unmet Needs of the ACS Market have Encouraged R&D

9.3 Oral Anticoagulants in Development: Progress and Setbacks

9.3.1 Apixaban, Bristol-Myers Squibb/Pfizer Filed for VTE, but Setback for Development in ACS Patients

9.3.2 Xarelto (Rivaroxaban), Bayer HealthCare Pharma/Johnson & Johnson Pharmaceutical Research & Development

9.3.3 Pradaxa (Dabigatran), Boehringer Ingelheim

9.3.4 TAK-442 (Letaxaban), Takeda Pharmaceuticals

9.4 Novel Parenteral Anticoagulants: Offering Advantages over the Current Standard of Care?

9.4.1 Otamixaban, Sanofi-Aventis Rapid Onset of Action and Short Half-Life

9.4.2 REG1, Regado Biosciences First Aptamer Drug for the Treatment of ACS In Phase II Clinical Trials for ACS

9.5 Direct ADP Receptor Antagonists: Providing Rapid Onset and Offset of Action

9.5.1 Brilinta (Ticagrelor), AstraZeneca Rejected for Reimbursement in France: Another Setback after Delay of Approval in the US Factors Favouring Brilinta: A New Class of Drug

9.5.2 Elinogrel (PRT128), Novartis/Portola Pharmaceuticals

9.5.3 Cangrelor, The Medicines Company

9.6 Thrombin Receptor Antagonists: Novel Antiplatelet Drugs

9.6.1 Vorapaxar, Merck & Co. Setback for a Promising Candidate

9.6.2 E555 (Atopaxar), Eisai

9.7 Other Drugs in Development for ACS

10. Qualitative Analysis of the Industry and Market

10.1 Strengths and Weaknesses of the Sector

10.1.1 Increasing Prevalence of Disease Drives the Market

10.1.2 High Mortality Rates: Leading Cause of Death in Developed Countries

10.1.3 Available Treatments Have Been Successful in Reducing Mortality Rate

10.1.4 High Economic Cost of Disease

10.2 Opportunities and Threats

10.2.1 Developing Countries: Expanding New Markets

10.2.2 Managing Risk Factors and Opportunity for Growth of Drugs Used for Secondary Prevention

10.2.3 Novel Therapeutics Poised to Meet Needs in the Patient Population

10.2.4 Switching to OTC

10.2.5 The Threat of Generic Products

10.2.6 Termination of Late-Stage Clinical Trials

10.2.7 Downward Cost Pressures

10.2.8 A Buyer's Market?

10.2.9 Challenges to the Statin Drug Industry and Market

11. Opinion from Our Survey

11.1 Interview with Dr Mauricio Cohen, Associate Professor of Medicine, University of Miami Miller School of Medicine; Director, Cardiac Catheterization Laboratory, University of Miami Hospital, US

11.1.1 Regado Biosciences' Lead Pipeline Anticoagulant Drug Candidate: REG1

11.1.2 Advantages Offered by the REG1 Anticoagulation System

11.1.3 Unmet Needs and Future of ACS Treatment Development

12. Conclusions

12.1 Principal Market Drivers

12.2 Principal Market Restraints

12.3 Driving Factors for the Success of Pipeline Drugs

12.4 Concluding Remarks on the Future of the Market

List of Tables

Table 2.1 Hospital Admissions in the US Due to ACS, by Type of Condition, 2007

Table 4.1 List of ACS Drugs Recommended by ACC/AHA and ESC

Table 4.2 World ACS Treatment Market by Leading Therapeutic Classes ($m), 2010

Table 4.3 Leading Drugs in the World ACS Treatment Market ($m), 2010

Table 4.4 Plavix: Total Sales and Sales from ACS ($m), 2009 & 2010

Table 4.5 World ACS Treatment Market Forecast ($m), 2010-2021

Table 4.6 Market Shares (%) of Leading Therapeutic Classes in the ACS Treatment Market, 2010, 2015 & 2021

Table 5.1 Platelet Aggregation Inhibitors Market by Leading Products ($m), 2010

Table 5.2 Platelet Aggregation Inhibitors Market Sales Forecast ($m), 2010-2021

Table 5.3 List of Clopidogrel Generics Approved in the EU

Table 5.4 Plavix Sales Forecast ($m), 2010-2021

Table 5.5 Effient/Efient Sales Forecast ($m), 2010-2021

Table 5.6 ReoPro Sales Forecast ($m), 2010-2021

Table 5.7 Integrilin Sales Forecast ($m), 2010-2021

Table 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2021

Table 5.9 Market Shares (%) of the Leading Drugs in the Platelet Aggregation Inhibitors Market, 2010, 2015, & 2021

Table 6.1 Anticoagulant Drugs Market by Leading Products ($m), 2010

Table 6.2 Anticoagulants Market Sales Forecast ($m), 2010-2021

Table 6.3 Lovenox: Total Sales and Sales in ACS ($m), 2009 & 2010

Table 6.4 Lovenox Sales Forecast ($m), 2010-2021

Table 6.5 Angiomax/Angiox Sales ($m) by Region, 2009 & 2010

Table 6.6 Angiomax/Angiox Sales Forecast ($m), 2010-2021

Table 6.7 Arixtra Sales ($m) by Region, 2009 & 2010

Table 6.8 Arixtra Sales Forecast ($m), 2010-2021

Table 6.9 Coumadin Sales Forecast ($m), 2010-2021

Table 6.10 Market Shares (%) of the Leading Drugs in the Anticoagulants Market, 2010, 2015 & 2021

Table 7.1 Fibrinolytics Drugs Market by Leading Products ($m), 2010

Table 7.2 Fibrinolytics Market Sales Forecast ($m), 2010-2021

Table 7.3 Metalyse/TNKase Sales Forecast ($m), 2010-2021

Table 7.4 Activase/Actilyse Sales Forecast ($m), 2010-2021

Table 8.1 Leading National Markets for ACS Drugs ($m), 2010

Table 8.2 Leading National Markets for ACS Drugs: Forecasts ($m), 2010-2021

Table 8.3 Leading National Markets: Market Shares (%), 2010, 2015 & 2021

Table 9.1 Key Pipeline Products for the Treatment of ACS, 2011

Table 9.2 Comparison of Marketed and Pipeline Oral Anticoagulants, 2011

Table 9.3 Comparison of Marketed and Pipeline Parenteral Anticoagulant Drugs, 2011

Table 9.4 Comparison of Marketed and Pipeline ADP Receptor Antagonist Drugs, 2011

Table 10.1 SWOT Analysis of the World ACS Treatment Industry and Market, 2011

Table 10.2 Patent Expiries of Some Marketed ACS Drugs

List of Figures

Figure 2.1 Clinical Conditions Grouped Under ACS

Figure 2.2 Classification of ACS Conditions

Figure 2.3 Shares (%) of Hospital Admissions in the US by Type of Condition, 2007

Figure 3.1 Treatment for ACS: Mechanical and Pharmacological Therapy, 2011

Figure 3.2 Use of Drug Therapy for ACS Treatment, 2011

Figure 4.1 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2010

Figure 4.2 Sales ($m) of Leading Drugs in the World ACS Treatment Market, 2010

Figure 4.3 World ACS Treatment Market Forecasts ($m), 2010-2021

Figure 4.4 Forecasts ($m) for Leading Therapeutic Classes of the ACS Treatment Market, 2010-2021

Figure 4.5 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2015

Figure 4.6 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2021

Figure 5.1 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2010

Figure 5.2 Platelet Aggregation Inhibitors Market: Sales Forecast ($m), 2010-2021

Figure 5.3 Plavix Sales Forecast ($m), 2010-2021

Figure 5.4 Effient/Efient Sales Forecast ($m), 2010-2021

Figure 5.5 ReoPro Sales Forecast ($m), 2010-2021

Figure 5.6 Integrilin Sales Forecast ($m), 2010-2021

Figure 5.7 Aspirin Cardio Sales Forecast ($m), 2010-2021

Figure 5.8 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2015

Figure 5.9 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2021

Figure 6.1 Market Shares (%) of Leading Anticoagulant Drugs, 2010

Figure 6.2 Anticoagulants Market Sales Forecast ($m), 2010-2021

Figure 6.3 Lovenox Sales Forecast ($m), 2010-2021

Figure 6.4 Angiomax/Angiox Sales Forecast ($m), 2010-2021

Figure 6.5 Arixtra Sales Forecast ($m), 2010-2021

Figure 6.6 Coumadin Sales Forecast ($m), 2010-2021

Figure 6.7 Market Shares (%) of Leading Anticoagulants, 2015

Figure 6.8 Market Shares (%) of Leading Anticoagulants, 2021

Figure 7.1 Market Shares (%) of Leading Fibrinolytic Drugs, 2010

Figure 7.2 Fibrinolytics Market Sales Forecast ($m), 2010-2021

Figure 7.3 Metalyse/TNKase Sales Forecast ($m), 2010-2021

Figure 7.4 Activase/Actilyse Sales Forecast ($m), 2010-2021

Figure 8.1 ACS Treatment Market Shares (%) by Country, 2010

Figure 8.2 ACS Treatment Market Shares (%) by Country, 2015

Figure 8.3 ACS Treatment Market Shares (%) by Country, 2021

Figure 8.4 The US ACS Treatment Market Forecast ($m), 2010-2021

Figure 8.5 The Japanese ACS Treatment Market Forecast ($m), 2010-2021

Figure 8.6 ACS Treatment Market Forecasts for Leading European Countries ($m), 2010-2021

Figure 8.7 Indian and Chinese ACS Treatment Market Forecasts ($m), 2010-2021

Companies Listed

Abbott Laboratories


Acino Pharma


American College of Cardiology (ACC)

American Heart Association (AHA)

Amphastar Pharmaceuticals

Anthera Pharmaceuticals



APP Pharmaceuticals

Astellas Pharma


Barr Pharmaceuticals

Bayer HealthCare Pharma

Bharat Biotech International

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

British Heart Foundation

Centocor Ortho Biotech

Cerenis Therapeutics

Cobalt Pharmaceuticals Company

COR Therapeutics

Corimmun GmbH

CSL Behring

Daiichi Sankyo

Dr. Reddy's Laboratories


EKR Therapeutics

Eli Lilly

European Commission (EC) 

European Medicines Agency (EMA)

European Society for Cardio-Thoracic Surgery (EACTS)

European Society of Cardiology (ESC)

Food and Drug Administration (US FDA) 

French Transparency Commission 

Fresenius Kabi Group


Genzyme Corporation


HCS bvba

Hoffmann-La Roche


Iroko Cardio International

ISU Abxis 

Johnson & Johnson

Korean FDA


Kyowa Hakko Kirin


Merck & Co.

Millennium Pharmaceuticals

Mitsubishi Kasei 

Momenta Pharmaceuticals




Portola Pharmaceuticals

Procorde GmbH


Regado Biosciences






Society for Cardiovascular Angiography and Interventions (SCAI)

Sun Pharmaceutical Industries

Tad Pharma 

Takeda Pharmaceuticals Company

Taro Pharmaceutical Industries

Teva Pharmaceutical Industries

The Arrow Group

The Medicines Company

Trigen GmbH

U.S. Patent and Trademark Office (USPTO)

VIA Pharmaceuticals

Viron Therapeutics

Watson Pharmaceuticals

To order this report:

Drug and Medication Industry: Acute Coronary Syndrome (ACS) Drug Market 

Drug and Medication Business News

More  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
2. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
3. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
4. NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction
5. Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
6. International Medical Corps Team in Hardest-Hit Coastal Communities Finds Severe Shortages of Food, Water, Medicines; Acute Need for Mental Health Support
7. Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
8. Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS
9. University Hospitals Selects Allscripts Electronic Health Record for 1,400 Physicians and Expands Sunrise™ Enterprise Acute Care EHR in Eight Hospitals
10. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
11. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 Research and Markets ... "Global Intrauterine Devices Market 2015-2019" report to ... --> In this report, the author the present ... market for 2015-2019. To calculate the market size, the ... type of products: Hormonal IUDs and copper IUDs. The ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... meeting. They observed that both STEMI and Sepsis conditions present in similar ways and ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
Breaking Medicine News(10 mins):